APOE and Hypertension: In UK Biobank, when compared to the non-APOE ε4 group, APOE ε4 carriers had a 1% higher MCF 95% (CI 0–1%, p = 0.020) which persisted after adjusting for age, sex and SEP (Model 2, p = 0.080), CVD (Model 4, p = 0.006), high cholesterol (Model 5, p = 0.0001) or hypertension (Model 7, p = 0.034), but was attenuated to 0% (95% CI 0–1%) after adjusting for BMI (Model 3, p = 0.079) or diabetes (p = 0.058, Table 6, Fig. 1).